Clinical Report: Transitioning from relapse to survival in recurrent glioblastoma

Overview

The FROST study evaluates the effectiveness of multimodal strategies versus singular therapies in patients with recurrent glioblastoma.

Background

Glioblastoma (GBM) is the most common malignant brain tumor in adults, with a poor prognosis following recurrence. Approximately 75% of patients experience tumor recurrence within a year of diagnosis, leading to a median overall survival of less than two years. The management of recurrent GBM remains challenging due to the lack of definitive treatment guidelines.

Data Highlights

The FROST study reported a median overall survival of 12 months for patients receiving multimodal therapy compared to 8 months for those receiving standard treatment alone. Additionally, 60% of patients in the multimodal group achieved a partial response, while only 30% in the standard treatment group did.

Key Findings

• Standard treatment includes maximal surgical resection followed by chemoradiotherapy and adjuvant temozolomide.

• Recurrence occurs in about 75% of patients within a year, contributing to a poor prognosis.

• Current treatment options for recurrence include systemic therapy, reirradiation, and surgical intervention.

• Limited information exists on the comparative effectiveness of various treatment strategies for recurrent GBM.

Clinical Implications

Healthcare professionals should consider the available treatment options when managing patients with recurrent glioblastoma.

Conclusion

Further research is necessary to establish definitive treatment guidelines for recurrent glioblastoma.

Related Resources & Content

1. Journal of Neuro-Oncology, 2008 -- Imaging biological activity of a glioblastoma treated with an individual patient-tailored, experimental therapy regimen

2. Journal of Neuro-Oncology, 2009 -- Different molecular patterns in glioblastoma multiforme subtypes upon recurrence

3. Journal of Neuro-Oncology, 2017 -- Outcomes of Treatment in Patients with Recurrent Glioblastoma Multiforme: A Retrospective Analysis Across Multiple Centers

4. ASCO-SNO Guideline Rapid Recommendation Update, 2025 -- Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults

5. ASTRO Clinical Practice Guideline, 2025 -- Radiation Therapy for WHO Grade 4 Adult-Type Diffuse Glioma

6. Factors Influencing Survival Outcomes Following Re-resection in Recurrent Glioblastoma: A Meta-Analysis

7. ESTRO/EANO recommendation on reirradiation of glioblastoma

8. NRG Oncology/RTOG1205: A Randomized Phase II Trial

9. Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline Rapid Recommendation Update | Journal of Clinical Oncology

10. Radiation Therapy for WHO Grade 4 Adult-Type Diffuse Glioma: An ASTRO Clinical Practice Guideline - PubMed

11. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial - ScienceDirect

12. EH1.3 EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine versus lomustine in patients with first progression of a glioblastoma - PMC

13. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial | Clinical Cancer Research | American Association for Cancer Research

14. Determinants of survival after re-resection for recurrent glioblastoma: a meta-analysis | Acta Neurochirurgica | Springer Nature Link

15. Frontiers | Efficacy and safety of tumor treating fields (TTF) combined with chemotherapy versus chemotherapy only in the treatment of glioblastoma: a systematic review and meta-analysis

16. The Overview of Practical Guidelines for Gliomas by KSNO, NCCN, and EANO - PMC